Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.

Eastell R, Chen P, Saag KG, Burshell AL, Wong M, Warner MR, Krege JH

Bone6 Jan 2010Cited by 25 (Europe PMC)

PMID20060078DOI10.1016/j.bone.2009.12.021PepBankPUB-20060078

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with glucocorticoid-induced osteoporosis, median osteocalcin increased by 92% during teriparatide therapy.
In plain wordsIn patients with glucocorticoid-induced osteoporosis, osteocalcin increased from baseline during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum osteocalcin
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 mug/day · subcutaneousAs given in this study (human).
Measurements
Median osteocalcin increase
92%
teriparatide
Source sentences
Summary
On teriparatide therapy, the median OC and PINP levels increased by 92% and 108%, respectively, and this resulted in only 12% and 1% of patients being low at 6 months.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind study, women (N=159) and men (N=38) with GIO were randomized to either teriparatide 20 mug/day by subcutaneous injection or to alendronate 10 mg/day orally.
Report a problemFND-2006007801
02HumanRandomized controlled trialEfficacy outcome
In patients with glucocorticoid-induced osteoporosis, median PINP increased by 108% during teriparatide therapy.
In plain wordsIn patients with glucocorticoid-induced osteoporosis, PINP increased from baseline during teriparatide treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseSerum PINP
Study
n: not reported in source
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 mug/day · subcutaneousAs given in this study (human).
Measurements
Median PINP increase
108%
teriparatide
Source sentences
Summary
On teriparatide therapy, the median OC and PINP levels increased by 92% and 108%, respectively, and this resulted in only 12% and 1% of patients being low at 6 months.
1 context sentence(design, population, supporting numbers)
Summary · context
In a double-blind study, women (N=159) and men (N=38) with GIO were randomized to either teriparatide 20 mug/day by subcutaneous injection or to alendronate 10 mg/day orally.
Report a problemFND-2006007802
03HumanRandomized controlled trialEfficacy outcome
In teriparatide-treated patients with glucocorticoid-induced osteoporosis, 12% had osteocalcin below the reference interval at 6 months.
In plain wordsAt 6 months, 12% of patients receiving teriparatide had low osteocalcin.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedLow osteocalcin prevalence
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 mug/day · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Low osteocalcin
12%
teriparatide at 6 months
Source sentences
Summary
On teriparatide therapy, the median OC and PINP levels increased by 92% and 108%, respectively, and this resulted in only 12% and 1% of patients being low at 6 months.
2 context sentences(design, population, supporting numbers)
Summary · context
Baseline bone formation markers were below the reference interval (low) in 33% of patients for OC and in 4% of patients for PINP.
Summary · context
In a double-blind study, women (N=159) and men (N=38) with GIO were randomized to either teriparatide 20 mug/day by subcutaneous injection or to alendronate 10 mg/day orally.
Report a problemFND-2006007803
04HumanRandomized controlled trialEfficacy outcome
In teriparatide-treated patients with glucocorticoid-induced osteoporosis, 1% had PINP below the reference interval at 6 months.
In plain wordsAt 6 months, 1% of patients receiving teriparatide had low PINP.
Peptide
Teriparatide (PTH 1-34)
Outcome
Direction not reportedLow PINP prevalence
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 mug/day · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Low PINP
1%
teriparatide at 6 months
Source sentences
Summary
On teriparatide therapy, the median OC and PINP levels increased by 92% and 108%, respectively, and this resulted in only 12% and 1% of patients being low at 6 months.
2 context sentences(design, population, supporting numbers)
Summary · context
Baseline bone formation markers were below the reference interval (low) in 33% of patients for OC and in 4% of patients for PINP.
Summary · context
In a double-blind study, women (N=159) and men (N=38) with GIO were randomized to either teriparatide 20 mug/day by subcutaneous injection or to alendronate 10 mg/day orally.
Report a problemFND-2006007804

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.